title: Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients.
abstract: Immunosuppressive regimens including mycophenolate mofetil (MMF, Cellcept) were used in a renal transplant transplant program since May 2000 including 67 patients in whom it was the primary drug. Acute rejection (AR) occurred in 9 cases (13%) with 1-year graft survival rate of 96.8%. Pharmacokinetic (PK) studies of mycophenolic acid (MPA) were performed in 46 recent patients (total, 127 times). There was no correlation between dose (mg/kg) and blood concentration (AUC0-9: r2= 0.27). AUC0-9 was well correlated with AUC0-4 (r2= 0.91), but not with a single timepoint concentration. MPA AUC0-9 level was significantly higher among the AR-negative group (n = 33; 34.2 +/- 16.8 ng.hr/mL) compared with AR-positive group (n = 3; 28.2 +/- 1.9 ng.hr/mL; P = .04085) over the 2 weeks after transplantation. MPA AUC0-9 level was higher among the adverse event (AE-positive) group (n = 15; 39.2 +/- 22.8 ng.hr/mL) compared with the negative group (n = 21; 30.1 +/- 8.0 ng.hr/mL; P = .08772) within 2 weeks after transplantation. These results suggest the necessity of measuring AUC for therapeutic drug monitoring (TDM) of MMF-containing immunosuppressive therapy. The possible target level of MPA AUC0-9 would be approximately 30 ng.hr/mL using the present immunosuppressive regimen.
authors.affiliation: Department of Transplantation and Regenerative Surgery, Graduate School of Medical Science, Kyoto, Japan. amoto@koto.kpu-m.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Okamoto
authors.forename: Y
authors.initials: Y
authors.lastname: Wakabayashi
authors.forename: A
authors.initials: A
authors.lastname: Higuchi
authors.forename: Y
authors.initials: Y
authors.lastname: Kadotani
authors.forename: S
authors.initials: S
authors.lastname: Ogino
authors.forename: H
authors.initials: H
authors.lastname: Ushigome
authors.forename: K
authors.initials: K
authors.lastname: Akioka
authors.forename: S
authors.initials: S
authors.lastname: Kaihara
authors.forename: N
authors.initials: N
authors.lastname: Yoshimura
mesh_terms: D000293:Adolescent; D000328:Adult; D002102:Cadaver; D002648:Child; D016572:Cyclosporine / Q000627:therapeutic use; D016903:Drug Monitoring / Q000379:methods; D006084:Graft Rejection / Q000453:epidemiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality; D019520:Living Donors; D008875:Middle Aged; D009173:Mycophenolic Acid / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016019:Survival Analysis; D014019:Tissue Donors
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine; D009173:Mycophenolic Acid